STOCK TITAN

Rapport Therapeutics CEO sells 2,210 shares

The sales were made under Rule 10b5-1 trading plans adopted on March 27, 2026.

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. Chief Executive Officer Ceesay Abraham sold 2,210 shares of common stock on September 23, 2026, in three transactions: 1,952 shares at a weighted average price of $39.0523, 215 shares at a weighted average price of $39.8602, and 43 shares at $41.0500 per share. The sales were made under Rule 10b5-1 trading plans adopted on March 27, 2026. Abraham's reported indirect holdings included 81,729 shares through Ceesay Family Irrevocable Trust and 20,729 shares through Dorothy Ceesay Irrevocable Trust.

Positive

  • None.

Negative

  • None.
Insider Ceesay Abraham
Role Chief Executive Officer
Sold 2,210 shs ($87K)
Type Security Shares Price Value
Sale Common Stock F1, F2 1,952 $39.0523 $76K
Sale Common Stock F1, F3 215 $39.8602 $9K
Sale Common Stock F1 43 $41.05 $2K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 456,767 shares (Direct); Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust); Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Footnotes (3)
  1. F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Shares sold, transaction 1 1,952 shares September 23, 2026
Weighted average price, transaction 1 $39.0523 per share September 23, 2026
Shares sold, transaction 2 215 shares September 23, 2026
Weighted average price, transaction 2 $39.8602 per share September 23, 2026
Shares sold, transaction 3 43 shares September 23, 2026
Price, transaction 3 $41.0500 per share September 23, 2026
Indirect shares through Ceesay Family Irrevocable Trust 81,729 shares Reported September 23, 2026
Indirect shares through Dorothy Ceesay Irrevocable Trust 20,729 shares Reported September 23, 2026
Rule 10b5-1 trading plans regulatory
"pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026"
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Irrevocable Trust financial
"By Ceesay Family Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RAPP shares did CEO Ceesay Abraham sell?

Ceesay Abraham, Rapport Therapeutics' Chief Executive Officer, sold 2,210 shares on September 23, 2026, in three transactions.

What price ranges were reported for the RAPP CEO's September 23 sales?

For the 1,952-share transaction, the weighted average price was $39.0523, with sales from $38.54 to $39.48, inclusive. For the 215-share transaction, the weighted average price was $39.8602, with sales from $39.57 to $40.25, inclusive. A separate 43-share transaction was reported at $41.0500 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ceesay Abraham

(Last)(First)(Middle)
RAPPORT THERAPEUTICS, INC.
99 HIGH STREET, SUITE 2100

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/23/2026S(1)1,952D$39.0523(2)457,025D
Common Stock09/23/2026S(1)215D$39.8602(3)456,810D
Common Stock09/23/2026S(1)43D$41.05456,767D
Common Stock81,729IBy Ceesay Family Irrevocable Trust
Common Stock20,729IBy Dorothy Ceesay Irrevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
/s/ Troy Ignelzi, Attorney-in-Fact09/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading